Genzyme Care Coordination
Personalized Support
Genzyme Case Managers provide free and confidential care coordination, support and services to individuals living with Gaucher disease and their health care providers who reside in the United States. Our Case Managers will work closely with you, your staff and your patient to help coordinate access to treatment with Cerezyme®.
By referring your patients to a Genzyme Case Manager, they will have access to comprehensive care coordination services that include:
Personalized Case Management
Your patient will be assigned their own Case Manager who will provide:
- One-on-one support tailored to you and your patient’s needs
- Information about treatment with Cerezyme and related insurance coverage
- Educational materials about Gaucher disease
- Access to other Genzyme resources, including field-based support for you and your staff
Reimbursement Support
Simplify the reimbursement process for you and your staff by helping to:
- Navigate the reimbursement process for treatment with Cerezyme
- Verify your patient’s insurance coverage for treatment
- Obtain a prior authorization, if necessary
- Assist with billing and claims issues, including appeals for denied claims
Your Call, Our Commitment
A Genzyme Case Manager is only a phone call away from providing personalized assistance to you, your staff and your patients.
1-800-745-4447, Option 3
Monday through Friday, 8:00 AM to 6:00 PM EST
Information you or your patients provide will always be kept confidential. Genzyme offers all Care Coordination services in compliance with patient privacy regulations (HIPAA).
Indication & Usage
Cerezyme® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:
- anemia
- thrombocytopenia
- bone disease
- hepatomegaly or splenomegaly
Important Safety Information
Approximately 15% of patients have developed IgG antibodies, and these patients have a higher risk of hypersensitivity reaction. Therefore periodic monitoring is suggested; caution should be exercised in patients with antibodies or prior symptoms of hypersensitivity. Symptoms suggestive of hypersensitivity occurred in 6.6% of patients, and include anaphylactoid reaction, pruritus, flushing, urticaria, angioedema, chest discomfort, dyspnea, coughing, cyanosis and hypotension.
Reactions related to Cerezyme administration have been reported in less than 15% of patients. Each of the following events occurred in less than 2% of the total patient population. Reported adverse events include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and tachycardia. Adverse events associated with the route of administration include discomfort, pruritus, burning, swelling or sterile abscess at the site at the site of injection.
To report suspected adverse reactions, contact Genzyme at 800-745-4447, option 2 or FDA at 800-FDA-1088 or http://www.fda.gov/Safety/MedWatch
Please see Full Prescribing Information (PDF).